Q3 2024 Earnings Call Transcript October 29, 2024 Novartis AG beats earnings expectations. Reported EPS is $2.06, expectations were $1.96. Operator: Good morning and good afternoon, and welcome to the ...

We continue to see very strong performance in hypertension in China. In Japan ... And moving to slide nine, Kisqali continued to cement its leadership in metastatic breast cancer, and launched ...

Regulatory reviews for Kisqali as an EBC treatment are ongoing worldwide, including in the EU and China. Kisqali has been approved as a treatment for metastatic breast cancer (MBC) patients in 99 ...

Novartis AG ( (NVS) ) has realeased its Q3 earnings. Here is a breakdown of the information Novartis AG presented to its investors. Novartis AG ...

NVS' third-quarter earnings and sales beat estimates. Based on the strong momentum of key drugs, the company raises its ...

China, Germany and Japan. Novartis’ efforts to strengthen its wide portfolio by developing breakthrough treatments have made it even more formidable in this space. Cosentyx, Entresto, Kesimpta, ...

On Tuesday, Novartis AG (NYSE:NVS) reported third-quarter sales of $12.823 billion, up 9% (+10% on constant currency), ...

Regulatory reviews for Kisqali as an EBC treatment are ongoing worldwide, including in the EU and China. This media update contains forward-looking statements within the meaning of the United States ...

Taiwan and relations with Russia Beijing may also be looking for ways to utilize Trump’s penchant for deal-making, including on the issue of Taiwan. China’s ruling Communist Party claims the ...